Insulet Rises to 470th in Trading Volume as Q2 Revenue Surges 32.9 and Margins Expand

On August 12, 2025, Insulet (PODD) recorded a trading volume of $220 million, ranking 470th in market activity, with the stock rising 1.57%.

Insulet’s second-quarter 2025 results highlighted strong revenue growth and margin expansion. GAAP revenue reached $649.1 million, exceeding estimates by 5.7% and rising 32.9% year-over-year. International Omnipod sales surged 45%, driven by successful market expansions in the U.K., Germany, and France. U.S. Omnipod revenue grew 28.7% to $453.2 million, supported by prior-year stocking dynamics and rebate timing. The company’s gross margin expanded to 69.7%, while adjusted operating income jumped 119.4% year-over-year. Insulet also raised full-year revenue guidance to 24%-27% constant currency growth, up from prior expectations of 19%-22%.

Key drivers included robust new customer acquisition for type 1 and type 2 diabetes, with over 30% of U.S. Omnipod starters in Q1 2025 being type 2 users. Product innovation, such as the Omnipod 5 iPhone app and compatibility with next-generation CGMs, further strengthened demand. Strategic investments in direct-to-consumer marketing and salesforce expansion also contributed to growth. However, a $84.4 million charge for early debt extinguishment impacted GAAP net income, though adjusted metrics remained resilient.

The strategy of buying the top 500 stocks by daily trading volume and holding them for one day resulted in a moderate return. The total profit from this strategy, considering the given time period from 2022 to the present, is $2,550. The maximum drawdown during this period was -15.2%, which occurred on October 27, 2022. This indicates that while the strategy has been profitable overall, it has experienced significant volatility and there have been periods of substantial loss.